Cite
RE‐START: Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine.
MLA
Romero, del Rincón, Celia, et al. “RE‐START: Exploring the Effectiveness of Anti‐calcitonin Gene‐related Peptide Resumption after Discontinuation in Migraine.” European Journal of Neurology, vol. 31, no. 4, Apr. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1111/ene.16203.
APA
Romero, del R. C., Gonzalez, M. A., Quintas, S., García, A. D., Fernández, L. I., Guerrero, P. A. L., Gonzalez, O. Y., Santos, L. S., González, O. C., Sánchez, R. N., Iglesias, D. F., Echavarría, Í. A., Gil, L. S., Huerta, V. M., Campoy, D. S., Muñoz, V. A., Lozano, R. A., Sánchez, S. A., Velasco, J. F., & Kortazar, Z. I. (2024). RE‐START: Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine. European Journal of Neurology, 31(4), 1–10. https://doi.org/10.1111/ene.16203
Chicago
Romero, del Rincón, Celia, Martinez, Alicia Gonzalez, Sonia Quintas, Azorín, David García, Lázaro, Iris Fernández, Peral, Angel Luis Guerrero, Osorio, Yesica Gonzalez, et al. 2024. “RE‐START: Exploring the Effectiveness of Anti‐calcitonin Gene‐related Peptide Resumption after Discontinuation in Migraine.” European Journal of Neurology 31 (4): 1–10. doi:10.1111/ene.16203.